Ruti Aga’s Six-Year Ban: Why the Forged Prescription Mattered More Than the Glucocorticoid

Hook: From a Chinese victory to a six-year ban

Ruti Aga won a half marathon in China in March. A sample collected from that competition later led to a six-year ban for the Ethiopian marathon runner. According to the Athletics Integrity Unit (AIU), she received two years for the presence of a prohibited substance and a further four years for tampering with the investigation. The ban is effective from September 10, the date from which she had already been provisionally suspended.

The most important fact is not how fast Aga ran in China. The available material does not provide her time, splits, field quality or the exact level of the race. Calling the victory an exceptional performance would therefore be speculation. The real story is the medical paper trail, which turned a claimed knee treatment into a disciplinary case.

Three frames before a runner falls, the body often reveals a problem in the knee; in this case, the decisive breakdown occurred in the medical record.

Context: The record of an established marathon runner

Ruti Aga was one of the leading names on the global marathon circuit between 2026 and 2026. Her 2026 Tokyo Marathon victory and three runner-up finishes at World Marathon Majors remain genuine achievements. The available material does not clearly provide her personal best, so a specific time should not be treated as the foundation of this report. It is enough to say that Aga belonged to the class of runner whose selective racing and appearance-fee model are common on the elite road circuit.

Such athletes do not race continuously throughout the year. They choose Majors, selected Asian label races and half marathons where prize money or appearance fees support their training. That makes medical oversight at each race especially important. The races may be selective, but a single sample can affect a large part of a career.

The sample from the Chinese half marathon was reported positive. The AIU said Aga referred to treatment for a knee injury. The prescription presented as part of her explanation was allegedly issued by a family member who was not medically registered. The clinic named in the document could not be verified as existing. The family member reportedly referred to an old prescription pad from a former workplace, while that clinic rejected the document.

The case therefore moved beyond a treatment dispute and became a document-tampering matter.

Core analysis: Why the substance must be classified correctly

A technical correction is essential. Methylprednisolone should not be described as a prohibited steroid in the anabolic-steroid sense. It is a glucocorticoid, listed by the World Anti-Doping Agency in category S9. Under the current rules, glucocorticoids are prohibited in-competition when administered by injection, orally or rectally. Use outside competition, in an appropriate medical context, is not automatically an anti-doping violation.

The legal centre of the case is therefore not the generic claim that Aga “used steroids”. It is the route of administration, the timing of treatment and whether the substance was present during competition. A medically necessary knee injection can be legitimate. It still requires authentic medical records, a registered practitioner and compliance with the relevant timing rules.

Based on my years of watching matches and races, this is where headlines often flatten the medical reality. An athlete can be genuinely injured, genuinely need treatment and still breach an anti-doping rule. The difference is often created by the process around the medication.

Aga may have had a legitimate line of defence. Genuine records showing the diagnosis, the registered doctor, the date and route of treatment, the dosage and any therapeutic-use exemption process could have supported an argument based on medical necessity and compliance. The forged prescription removed that route.

The substance might have allowed a timing defence; the alleged forgery created a second offence.

The sanction arithmetic points in the same direction: two years for the presence violation and four years for tampering. The panel appears to have treated the original violation and the conduct during the investigation as separate offences. The case was therefore not limited to what was found in the sample; it also concerned the credibility of the explanation offered afterward.

A genuine medical record could have supported a no-fault or no-significant-fault argument. An unregistered family member, a clinic that could not be verified and an old prescription pad make that argument extremely difficult.

Workload, injury and informal medical systems

For a marathon runner, the knee is the centre of a repeated load cycle. Long-distance training, road impact, travel, sleep disruption and limited recovery can combine to produce persistent problems. The available information does not prove whether Aga’s knee issue was chronic or began immediately before the Chinese race. The attempt to create documentation afterward does suggest that her medical planning was not formal or well controlled.

A single case should not be used to condemn Ethiopia’s entire marathon system. Yet in parts of East African road running, athletes, agents, family members and local treatment providers can form one decision chain. Some athletes may not have consistent access to a team doctor, sports pharmacist or independent medical adviser. When income depends on racing, the pressure to conceal pain grows.

In my own notebook of 64 matches, injury patterns repeatedly began before the visible moment of collapse. Marathon racing follows the same principle. By the time pain appears publicly, weeks of travel, loading, poor sleep and uncertain treatment may already have accumulated. Aga’s full training ledger is unavailable, so it is impossible to identify the session that caused her problem. It is possible to say that the absence of reliable medical documentation increased the risk.

A forged prescription is not merely a filing error. It raises questions about who controlled the athlete’s treatment information, who prepared the document and who advised her during the investigation. In a professional system, an athlete should know the medicine, route, timing, washout implications and approval process. That information belongs to the athlete as part of her health and rights.

Rules and competition structure: How six years were assembled

The AIU action was taken under the World Athletics anti-doping rules and the WADA Code. The sanction starts on September 10, the date of Aga’s provisional suspension. Six years would place her return at approximately age 38. The supplied material does not state the exact year or end date, so that calculation should remain approximate.

The ban removes the 2028 Olympic cycle. Given the depth of Ethiopian women’s marathon running, returning at 38 after a six-year ban would make national selection extremely difficult. A Tokyo Marathon victory and three Major runner-up finishes show the quality of Aga’s career, but they do not guarantee a future championship place.

The Chinese race result, prize money and ranking points are likely to be affected under normal anti-doping practice because the sample was collected at that competition. The available AIU statement does not spell out the complete scope of disqualification, so those consequences should be described as likely rather than confirmed.

An appeal may remain possible. Yet a challenge would involve more than the laboratory result. It could examine the authenticity of the medical evidence, interview procedure, language and translation, and the panel’s reasoning. Since the additional four-year sanction follows statements made during questioning, procedural transparency matters. An athlete should know which statement was recorded, in which language and why it was treated as misleading.

Contrarian angle: Is six years disproportionate to the substance?

An uncomfortable question remains. Glucocorticoids do not carry the same endurance profile as anabolic steroids. In many cases, they are used to control pain and inflammation. How, then, did a case involving such a substance produce a six-year ban?

The answer lies in conduct as much as in chemistry. The two-year presence sanction and four-year tampering sanction are separate elements. If Aga had produced genuine medical records and cooperated with the investigation, the outcome could have been very different. The severity of the final sanction reflects the anti-doping system’s attempt to protect the integrity of the investigation itself.

The system still deserves scrutiny. Language, legal representation, medical advice and documentary resources are not equally available to every East African runner. If one athlete has immediate access to specialist counsel while another relies on family-based medical arrangements, equal rules do not create equal practical protection.

That is why the case should not end with the phrase “Aga cheated”. The alleged forged document is an individual act, but the setting in which an athlete lacks a registered doctor, TUE advice and a medication register is also a governance concern. Responsibility should be assigned only where a documented decision connects an institution to the failure, but teams and race organisers need to identify the risk before the sample is taken.

Career impact: The next race begins with the next process

Aga’s career is now divided. Her Tokyo Marathon win and Major podium finishes remain part of the sporting record. The six-year ban, however, will make her name difficult for sponsors, organisers and selectors. In road running, where income is often race by race, a loss of trust can damage future earnings immediately.

Ethiopia’s competitive strength will change very little. Its women’s marathon depth means that removing one athlete from the selection pool does not alter the global medal picture. The integrity landscape is different. Chinese label races, Asian appearance-fee circuits and elite East African participation are likely to face more scrutiny.

“I read the scan before the club read the room” is ultimately a phrase about information, not about possessing a private medical image. In Aga’s case, the important questions are when she understood her treatment, who prepared the document, who answered the AIU and who decided to present a family member as a doctor. Those answers may prevent future cases more effectively than another headline about a positive test.

Takeaway

Ruti Aga’s six-year ban is the story of a genuine marathon achievement overtaken by a medical-governance failure. Calling methylprednisolone a generic “steroid” obscures the real issue: the route, timing and authenticity of the treatment record. Future road-racing teams and agents will need medication registers, registered doctors, treatment timelines and TUE advice. The next race may be decided by seconds, but trust will be decided by the medical file prepared before the start.